Literature DB >> 29740894

Epidemiology of prostate cancer in Asian countries.

Takahiro Kimura1, Shin Egawa1.   

Abstract

The incidence of prostate cancer has been increasing worldwide in recent years. The GLOBOCAN project showed that prostate cancer was the second most frequently diagnosed cancer and the fifth leading cause of cancer mortality among men worldwide in 2012. This trend has been growing even in Asian countries, where the incidence had previously been low. However, the accuracy of data about incidence and mortality as a result of prostate cancer in some Asian countries is limited. The cause of this increasing trend is multifactorial. One possible explanation is changes in lifestyles due to more Westernized diets. The incidence is also statistically biased by the wide implementation of early detection systems and the accuracy of national cancer registration systems, which are still immature in most Asian countries. Mortality rate decreases in Australia, New Zealand and Japan since the 1990s are possibly due to the improvements in treatment and/or early detection efforts employed. However, this rate is increasing in the majority of other Asian countries. Studies of latent and incidental prostate cancer provide less biased information. The prevalence of latent and incidental prostate cancer in contemporary Japan and Korea is similar to those in Western countries, suggesting the influence of lifestyle changes on carcinogenesis. Many studies reported evidence of both congenital and acquired risk factors for carcinogenesis of prostate cancer. Recent changes in the acquired risk factors might be associated with the increasing occurrence of prostate cancer in Asian countries. This trend could continue, especially in developing Asian countries.
© 2018 The Japanese Urological Association.

Entities:  

Keywords:  Asia; epidemiology; latent cancer; prostate cancer; risk factor

Mesh:

Year:  2018        PMID: 29740894     DOI: 10.1111/iju.13593

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  99 in total

Review 1.  Human microbiome and prostate cancer development: current insights into the prevention and treatment.

Authors:  Solmaz Ohadian Moghadam; Seyed Ali Momeni
Journal:  Front Med       Date:  2020-06-30       Impact factor: 4.592

2.  Aging-related tumor associated fibroblasts changes could worsen the prognosis of GBM patients.

Authors:  Hongwang Song; Xiaojun Fu; Chenxing Wu; Shouwei Li
Journal:  Cancer Cell Int       Date:  2020-10-08       Impact factor: 5.722

3.  Association between the baseline frailty and quality of life in patients with prostate cancer (FRAQ-PC study).

Authors:  Tomoko Hamaya; Shingo Hatakeyama; Masaki Momota; Takuma Narita; Hiromichi Iwamura; Yuta Kojima; Itsuto Hamano; Naoki Fujita; Teppei Okamoto; Kyo Togashi; Tohru Yoneyama; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2020-10-16       Impact factor: 3.402

4.  BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway.

Authors:  Zhenfeng Shi; Chutan Xiao; Tengceng Lin; Jieyin Wu; Ke Li
Journal:  Cell Cycle       Date:  2021-04-22       Impact factor: 4.534

Review 5.  Narrative review of urinary glycan biomarkers in prostate cancer.

Authors:  Shingo Hatakeyama; Tohru Yoneyama; Yuki Tobisawa; Hayato Yamamoto; Chikara Ohyama
Journal:  Transl Androl Urol       Date:  2021-04

6.  Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry.

Authors:  Rana R McKay; Theresa Gold; Jelani C Zarif; Ilkania M Chowdhury-Paulino; Adam Friedant; Travis Gerke; Marie Grant; Kelly Hawthorne; Elisabeth Heath; Franklin W Huang; Maria D Jackson; Brandon Mahal; Osarenren Ogbeide; Kellie Paich; Camille Ragin; Emily M Rencsok; Stacey Simmons; Clayton Yates; Jake Vinson; Philip W Kantoff; Daniel J George; Lorelei A Mucci
Journal:  JCO Glob Oncol       Date:  2021-04

7.  Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer.

Authors:  Takashi Ueda; Takumi Shiraishi; Saya Ito; Munehiro Ohashi; Toru Matsugasumi; Yasuhiro Yamada; Atsuko Fujihara; Fumiya Hongo; Koji Okihara; Osamu Ukimura
Journal:  Sci Rep       Date:  2021-05-12       Impact factor: 4.379

8.  Transcriptomic analysis of castration, chemo-resistant and metastatic prostate cancer elucidates complex genetic crosstalk leading to disease progression.

Authors:  Sayani Mukherjee; C Sudandiradoss
Journal:  Funct Integr Genomics       Date:  2021-06-29       Impact factor: 3.410

9.  Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.

Authors:  Yuka Kubota; Shingo Hatakeyama; Tohru Yoneyama; Mihoko Sutoh Yoneyama; Itsuto Hamano; Sakae Konishi; Teppei Okamoto; Hayato Yamamoto; Takahiro Yoneyama; Yasuhiro Hashimoto; Chikara Ohyama
Journal:  World J Urol       Date:  2021-03-06       Impact factor: 4.226

10.  Myelin and lymphocyte protein 2 regulates cell proliferation and metastasis through the Notch pathway in prostate adenocarcinoma.

Authors:  Chenglong Zheng; Ji Wang; Jian Zhang; Shujuan Hou; Yanfei Zheng; Qi Wang
Journal:  Transl Androl Urol       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.